NCT05890534View on ClinicalTrials.gov

Pycnogenol® in Post-COVID-19 Condition

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

November 5, 2024

Study Completion Date

December 31, 2024

Conditions
Post COVID-19 ConditionLong COVID
Interventions
DRUG

Pycnogenol®

Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.

DRUG

Placebo

Single center, quadruple blind randomized controlled trial comparing Pycnogenol® versus Placebo.

Trial Locations (1)

8001

University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Department of Public & Global Health, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT05890534 - Pycnogenol® in Post-COVID-19 Condition | Biotech Hunter | Biotech Hunter